RA Capital Healthcare Fund LP 4

What Happened
RA Capital Management, L.P. (a >10% holder) was granted an option covering 20,275 shares of Acrivon Therapeutics (ACRV) on 2026-06-17. The award shows an exercise price of $0.00 and a reported acquisition value of $0.00 (derivative award). The option vests subject to continuous service and other conditions described in the filing.

Key Details

• Transaction date: 2026-06-17; Form 4 filed 2026-06-22 (appears later than the typical 2-business-day Form 4 filing window).
• Transaction type/code: A (grant/award of a derivative option).
• Shares/options involved: option for 20,275 shares; exercise price reported $0.00; reported dollar value $0.00.
• Shares owned after transaction: not specified in the provided summary.
• Notable footnotes:
  • Vesting occurs the day before the issuer’s next annual meeting, subject to Dr. Derek DiRocco’s continuous service.
  • RA Capital acts as investment adviser to funds (RA Capital Healthcare Fund and RA Capital Nexus Fund II) and disclaims beneficial ownership except for pecuniary interest.
  • Dr. Derek DiRocco holds the option for the benefit of those funds and must remit any net cash or stock received on exercise to the adviser to offset advisory fees; the reporting parties disclaim beneficial ownership.
• Remark: Dr. Derek DiRocco is a partner at the adviser and serves on Acrivon’s board.

Context
This was a derivative award (option grant), not an open-market buy or sale — it does not by itself indicate a purchase or immediate sale of shares. The option is held for the benefit of institutional funds rather than as a personal holding of the adviser’s partners; reported mechanics indicate any proceeds would offset fees rather than remain with Dr. DiRocco. Institutional filings by investment managers (10% owners) often reflect fund arrangements and compensation structures rather than direct insider sentiment.